原发性皮肤间变性大细胞淋巴瘤的预后因素:西班牙皮肤淋巴瘤组多中心回顾性分析
一线治疗完全缓解率87%,5年特异性生存达93%;多发性皮肤病变、早期皮肤复发及淋巴结进展提示更差预后,淋巴结进展为独立预测因素。
要点
- 多发性皮肤病变、早期皮肤复发和淋巴结进展提示PCALCL预后更差。
- T2/T3期患者5年特异性生存低于T1期(84% vs 97%,P=0.031)。
- 淋巴结进展是缩短生存的独立预测因素(P=0.011)。
核心结论
- 多发性皮肤病变、早期皮肤复发和淋巴结进展提示PCALCL患者预后更差。
- 淋巴结进展是缩短生存的独立预测因素(P=0.011)。
研究设计与样本
- 采用方便抽样法,回顾性分析1986年5月至2017年8月在16个大学科室诊断的PCALCL患者。
主要发现
- 一线治疗完全缓解率为87%,手术、放疗、化疗或其他方法之间未见优势。
- 淋巴结进展率和内脏进展率分别为11%和2%。
- 5年特异性生存(SSV)达93%;T1患者为97%,T2/T3患者为84%(P=0.031)。
- 发生早期皮肤复发患者的5年SSV为64%,晚期或无复发者为96%(P=0.001)。
关键数值与推荐
- 出现淋巴结进展的患者估计中位SSV为103个月(95%CI:51-155个月)。
- 无淋巴结进展的患者估计SSV未达到中位(P<0.001)。
临床怎么用
- 对PCALCL患者应评估皮肤病变数目及分期,多发病变提示需更密切随访。
- 治疗选择上手术、放疗、化疗或其他方法未见生存优势,需个体化决策。
- 早期皮肤复发和淋巴结进展提示高危,应加强监测和干预。
局限性
- 采用方便抽样法,可能存在选择偏倚。
- 回顾性设计,诊断时间跨度大(1986-2017年),治疗策略可能随时间变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma (PCALCL) are lacking. OBJECTIVE: To identify prognostic factors for specific survival in patients with PCALCL. METHODS: Using the convenience sampling method, patients with PCALCL diagnosed from May 1986 to August 2017 in 16 University Departments were retrospectively reviewed. RESULTS: One hundred eight patients were included (57 males). Median age at diagnosis was 58 years. All of them showed T1-3N0M0 stages. Seventy per cent of the cases presented with a solitary lesion, mostly at the limbs. Complete response rate after first-line treatment was 87%, and no advantage was observed for any of them (surgery, radiotherapy, chemotherapy or other approaches). Nodal and visceral progression rate was 11% and 2%, respectively. 5-year specific survival (SSV) reached 93%; 97% for T1 patients and 84% for T2/T3 patients (P = 0.031). Five-year SSV for patients developing early cutaneous relapse was 64%; for those with late or no relapse, 96% (P = 0.001). Estimated median SSV for patients showing nodal progression was 103 months (95% CI: 51-155 months); for patients without nodal progression, estimated SSV did not reach the median (P < 0.001). Nodal progression was an independent predictive parameter for shorter survival (P = 0.011). CONCLUSION: Multiple cutaneous lesions at presentation, early skin relapse and nodal progression portrait worse prognosis in patients with PCALCL.
引用
- Fernández-de-Misa R, Hernández-Machín B, Combalía A, et al. Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. J Eur Acad Dermatol Venereol. 2019. PMID: 31591786. doi:10.1111/jdv.16006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。